南非将开始HIV疫苗试验

A new clinical trial is taking place in South Africa on an experimental vaccine that could safely prevent infection with HIV, the virus that causes AIDS.

According to a statement from the National Institutes of Health (NIH), the HVTN 702 is the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where some 7 million people are living with the virus.

The director of the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the NIH, Anthony S. Fauci said the new study is based on the one conducted in Thailand led by the U.S. Military HIV Research Program and the Thai Ministry of Health.

The study is expected to enroll 5,400 sexually active men and women between 18 and 35 at 15 sites across South Africa where more than 1,000 people a day are infected with HIV.

Results of the clinical trial are expected in 2020.

一种新的预防HIV的疫苗将在南非投入临床试验，这种疫苗有可能安全地预防造成艾滋病的HIV病毒的感染。

根据美国国立卫生研究院的声明，HVTN 702 是迄今在南非进行的最大规模、最先进的HIV疫苗临床试验。南非有大约7百万人携带HIV病毒。

美国国立卫生研究院下属的国家过敏和传染病研究院院长安东尼∙福奇表示，这项新研究是根据美国军方艾滋病毒研究项目和泰国卫生部先前在泰国进行的一项研究而制定的。

这次试验准备从南非的15个地点招收5400名18到35岁有性行为的男性和女性。在南非，每天感染HIV病毒的新患者超过1000人。

这次临床试验结果预计将于2020年公布。